US-based investment company McIntyre Partnerships delivered flat performance in H1 2026, returning 0% gross and -1% net compared to the Russell 2000 Value Index’s 23% return. A copy of the letter can be downloaded here. The second quarter results were a complete reversal of Q1 results, with the portfolio appreciating 23.0% (gross) and 23.3% (net), outperforming the index’s 17.3%. The overall market surge contributed to this performance, alongside several positive developments related to the firm’s holdings. Since inception, the fund has returned ~16% gross and ~12% net per annum, surpassing the benchmark’s return of ~9% per annum. The portfolio is highly concentrated, with QDEL as the largest holding, creating volatility. Despite mixed results, the firm remains confident in the portfolio, particularly with QDEL viewed as a key investment opportunity. Potential for further growth is expected from several large investments with promising catalysts. In addition, you can check the Strategy’s top 5 holdings to determine its best picks for 2026.
In its Q2 2026 investor letter, McIntyre Partnerships highlighted Sotera Health Company (NASDAQ:SHC). Sotera Health Company (NASDAQ:SHC) is a US-based company that provides sterilization solutions, lab testing, and advisory services for the healthcare industry. On August 7, 2026, Sotera Health Company (NASDAQ:SHC) closed at $18.86 per share, reflecting a market capitalization of $5.38 billion. Sotera Health Company (NASDAQ:SHC) posted a one-month return of 5.04%, while its shares gained 25.61% over the past 52 weeks.
McIntyre Partnerships stated the following regarding Sotera Health Company (NASDAQ:SHC) in its Q2 2026 investor letter:
“Sotera Health Company (NASDAQ:SHC) saw positive Q1 results, with the key Sterigenics segment continuing its return to HSD organic growth following the COVID destocking in 2023 and 2024. Further, SHC also had positive legal news regarding its Georgia litigation, where the judge threw out 5 lawsuits with reasoning that implies the remaining 450 cases are likely to be rejected as well. While I believe the judge’s ruling implies current liability is sub-$50MM, I estimate a worst-case $400k per case settlement, or $180MM, even if appeals reverse the decision. This compares to SHC’s 2026 EBITDA of ~$640MM. The company also saw a CEO transition, with its long-time CEO transitioning to Executive Chairman and the hiring of CEO Shader from Viant, a medical device services company where he served as CEO. We are encouraged that former CEO Petras remains on the board and intends to play an active role in ensuring a smooth transition.
Finally, and most importantly, following Q1 earnings, SHC’s former private equity owners sold the last of their shares. I believe the PE firms’ selling pressure, via predictable quarterly block trades, has been a considerable overhang on SHC’s shares over the past year. With this overhang gone, I believe SHC is well positioned to reweight towards peers. I estimate SHC can earn ~$1.30 in 2028, and an in-line valuation with similar growth med device companies would imply ~25x P/E, roughly double the current share price.”
Sotera Health Company (NASDAQ:SHC) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 42 hedge fund portfolios held Sotera Health Company (NASDAQ:SHC) at the end of the first quarter, up from 41 in the previous quarter. While we acknowledge the risk and potential of Sotera Health Company (NASDAQ:SHC) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Sotera Health Company (NASDAQ:SHC) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Sotera Health Company (NASDAQ:SHC) and shared O’Keeffe Stevens Advisory’s insight on the company. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
